Logo image of LUCD

LUCID DIAGNOSTICS INC (LUCD) Stock Fundamental Analysis

NASDAQ:LUCD - Nasdaq - US54948X1090 - Common Stock - Currency: USD

1.46  -0.03 (-2.01%)

After market: 1.4503 -0.01 (-0.66%)

Fundamental Rating

1

LUCD gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of LUCD have multiple concerns. LUCD is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LUCD has reported negative net income.
LUCD had a negative operating cash flow in the past year.
In the past 5 years LUCD always reported negative net income.
In the past 5 years LUCD always reported negative operating cash flow.
LUCD Yearly Net Income VS EBIT VS OCF VS FCFLUCD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of LUCD (-231.50%) is worse than 94.15% of its industry peers.
With a Return On Equity value of -825.40%, LUCD is not doing good in the industry: 90.43% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -231.5%
ROE -825.4%
ROIC N/A
ROA(3y)-137.83%
ROA(5y)-244.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LUCD Yearly ROA, ROE, ROICLUCD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -10K -20K -30K

1.3 Margins

LUCD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LUCD Yearly Profit, Operating, Gross MarginsLUCD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -5K -10K

More info and screens

1

2. Health

2.1 Basic Checks

LUCD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LUCD has more shares outstanding
The debt/assets ratio for LUCD is higher compared to a year ago.
LUCD Yearly Shares OutstandingLUCD Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M
LUCD Yearly Total Debt VS Total AssetsLUCD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

LUCD has an Altman-Z score of -14.98. This is a bad value and indicates that LUCD is not financially healthy and even has some risk of bankruptcy.
LUCD's Altman-Z score of -14.98 is on the low side compared to the rest of the industry. LUCD is outperformed by 85.11% of its industry peers.
A Debt/Equity ratio of 1.62 is on the high side and indicates that LUCD has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.62, LUCD is doing worse than 82.45% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.62
Debt/FCF N/A
Altman-Z -14.98
ROIC/WACCN/A
WACC8.65%
LUCD Yearly LT Debt VS Equity VS FCFLUCD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

LUCD has a Current Ratio of 1.18. This is a normal value and indicates that LUCD is financially healthy and should not expect problems in meeting its short term obligations.
LUCD's Current ratio of 1.18 is on the low side compared to the rest of the industry. LUCD is outperformed by 86.17% of its industry peers.
LUCD has a Quick Ratio of 1.14. This is a normal value and indicates that LUCD is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.14, LUCD is not doing good in the industry: 71.28% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.18
Quick Ratio 1.14
LUCD Yearly Current Assets VS Current LiabilitesLUCD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

LUCD shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.83%.
LUCD shows a strong growth in Revenue. In the last year, the Revenue has grown by 179.27%.
EPS 1Y (TTM)5.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.47%
Revenue 1Y (TTM)179.27%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%49.68%

3.2 Future

Based on estimates for the next years, LUCD will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.85% on average per year.
LUCD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 103.59% yearly.
EPS Next Y8.87%
EPS Next 2Y19.99%
EPS Next 3Y17.9%
EPS Next 5Y10.85%
Revenue Next Year86.13%
Revenue Next 2Y111.08%
Revenue Next 3Y138.99%
Revenue Next 5Y103.59%

3.3 Evolution

LUCD Yearly Revenue VS EstimatesLUCD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 20M 40M 60M 80M 100M
LUCD Yearly EPS VS EstimatesLUCD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LUCD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LUCD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LUCD Price Earnings VS Forward Price EarningsLUCD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LUCD Per share dataLUCD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as LUCD's earnings are expected to grow with 17.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.99%
EPS Next 3Y17.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LUCD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LUCID DIAGNOSTICS INC

NASDAQ:LUCD (2/21/2025, 8:00:00 PM)

After market: 1.4503 -0.01 (-0.66%)

1.46

-0.03 (-2.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-24 2025-03-24/amc
Inst Owners5.47%
Inst Owner Change-99.88%
Ins Owners8.08%
Ins Owner Change5.09%
Market Cap86.64M
Analysts83.33
Price Target4.08 (179.45%)
Short Float %2.29%
Short Ratio1.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6.95%
Min EPS beat(2)-11.41%
Max EPS beat(2)-2.5%
EPS beat(4)1
Avg EPS beat(4)-13.83%
Min EPS beat(4)-46.33%
Max EPS beat(4)4.93%
EPS beat(8)3
Avg EPS beat(8)-2.49%
EPS beat(12)4
Avg EPS beat(12)-7.2%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-10.6%
Min Revenue beat(2)-21.98%
Max Revenue beat(2)0.77%
Revenue beat(4)1
Avg Revenue beat(4)-7.66%
Min Revenue beat(4)-21.98%
Max Revenue beat(4)0.77%
Revenue beat(8)2
Avg Revenue beat(8)-9.29%
Revenue beat(12)2
Avg Revenue beat(12)-27.67%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.04%
EPS NY rev (1m)0%
EPS NY rev (3m)-11.51%
Revenue NQ rev (1m)2.91%
Revenue NQ rev (3m)5.45%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.73%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 20.68
P/FCF N/A
P/OCF N/A
P/B 13.67
P/tB 15.76
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.75
OCFYN/A
SpS0.07
BVpS0.11
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -231.5%
ROE -825.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-137.83%
ROA(5y)-244.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 1.62
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.45%
Cap/Sales 13.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.18
Quick Ratio 1.14
Altman-Z -14.98
F-Score5
WACC8.65%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)140.19%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.47%
EPS Next Y8.87%
EPS Next 2Y19.99%
EPS Next 3Y17.9%
EPS Next 5Y10.85%
Revenue 1Y (TTM)179.27%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%49.68%
Revenue Next Year86.13%
Revenue Next 2Y111.08%
Revenue Next 3Y138.99%
Revenue Next 5Y103.59%
EBIT growth 1Y13.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.2%
EBIT Next 3Y11.05%
EBIT Next 5Y6.9%
FCF growth 1Y-21.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.31%
OCF growth 3YN/A
OCF growth 5YN/A